Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Date of report (Date of earliest event reported): September 22, 2003
La Jolla Pharmaceutical Company
Delaware | 0-24274 | 33-0361285 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
6455 Nancy Ridge Drive, San Diego, California | 92121 | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code:(858) 452-6600
N/A
Item 5. Other Events and Required FD Disclosure. | ||||||||
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. | ||||||||
SIGNATURES | ||||||||
EXHIBIT INDEX | ||||||||
EXHIBIT 99.1 |
Table of Contents
Item 5. | Other Events and Required FD Disclosure. |
On September 22, 2003, the Company issued a press release announcing that Steven Engle, the Company’s Chief Executive Officer, would present at the UBS Warburg Global Life Sciences Conference on September 24, 2003. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 7. | Financial Statements, Pro Forma Financial Information and Exhibits. |
(c) | Exhibits. The following exhibits are filed with this report on Form 8-K: |
Exhibit | ||
Number | Description of Exhibit | |
99.1 | Press Release |
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LA JOLLA PHARMACEUTICAL COMPANY | ||
Date: September 22, 2003 | By: | /s/ Steven B. Engle Steven B. Engle Chairman and Chief Executive Officer |
Table of Contents
EXHIBIT INDEX
Exhibit | ||
Number | Description of Exhibit | |
99.1 | Press Release |